Research analysts covering Immuron.
Recent press releases and 8-K filings for IMRN.
Immuron CEO Presents Financial Achievements and Pipeline Updates at Conference
IMRN
Earnings
Guidance Update
New Projects/Investments
- Immuron Limited's CEO, Steven Lydeamore, presented at the Emerging Growth Conference on January 22, 2026, providing updates on the company's financial performance and product pipeline.
- For FY25, the company achieved global sales revenue of $7.3 million AUD, marking a 49% increase year-over-year, with a gross profit margin of 65.4%.
- In the first half of FY26, global sales revenue for Travelan® was $4.2 million AUD, up 5% compared to the first half of FY25.
- FY25 clinical achievements included FDA approval for IMM-529 IND and statistically significant results from the Travelan® Phase 2 trial.
- The FY26 outlook projects continued year-over-year sales growth and progression towards EBITDA (ex-R&D) breakeven, with IMM-529 Phase 2 initiation and a Travelan® End of Phase 2 Meeting with FDA both anticipated in 1H 2026.
Jan 23, 2026, 2:58 AM
Immuron Limited Announces Continued Sales Growth for H1 and Q2 2026
IMRN
Earnings
Product Launch
Revenue Acceleration/Inflection
- Immuron Limited reported unaudited global sales of AUD$4.2 million for H1 2026, representing a 5% increase on the prior comparative period, and AUD$2.2 million for Q2 2026, an 11% increase on the prior quarter.
- Australian H1 sales grew 13% to AUD$3.3 million, while U.S. H1 sales increased 17% to AUD$0.9 million compared to the prior comparative period.
- The company launched ProIBS® in Australia and anticipates launching Travelan® into Jean Coutu pharmacies in Canada in 3QFY26.
- Canadian Q2 sales showed a significant increase of 191% to AUD$42 thousand compared to the prior quarter, following a Q1 pipeline fill into over a thousand retail doors in FY25.
Jan 20, 2026, 12:01 PM
Immuron Reports Uniformed Services University Clinical Trial Primary Endpoint Not Met
IMRN
New Projects/Investments
Guidance Update
- Immuron Limited announced that the Uniformed Services University's clinical trial evaluating a third-party manufactured product containing enterotoxigenic E. coli (ETEC) hyperimmune bovine colostrum (IMM-124E) did not reach statistical significance for its primary endpoint.
- The company highlighted that the investigational product was not manufactured by Immuron and was not administered in accordance with Travelan® directions for use, which typically involves three times daily dosing before meals, unlike the twice-daily regimen used in the study.
- Immuron plans to propose the established and clinically validated three-times-daily dosing schedule for Travelan® at an upcoming End-of-Phase 2 meeting with the FDA.
- Immuron recently raised A$3.5 million by issuing 45.472 million shares to fund a Phase 2 clinical trial for IMM-529 and other objectives, and continues to progress towards EBITDA (ex R&D) breakeven.
Dec 10, 2025, 1:31 AM
Immuron Limited Applies for Quotation of New Ordinary Shares
IMRN
- Immuron Limited announced an application for the quotation of 45,472,000 new ordinary fully paid securities on the Australian Securities Exchange (ASX) on December 5, 2025.
- These securities were issued for a cash consideration at an issue price of AUD 0.07910000 per security.
- The shares were purchased by US investors through the company's US At-The-Market (ATM) facility.
- Following this quotation, the total number of ordinary fully paid securities on issue on the ASX will be 323,320,893.
Dec 5, 2025, 1:00 PM
Immuron Limited Announces Proposed Securities Issue
IMRN
New Projects/Investments
Capital Raise
- Immuron Limited announced a proposed issue of 45,472,000 ordinary fully paid securities.
- The securities will be issued for a cash consideration at an issue price of AUD 0.07910 per security.
- The proposed issue date is December 5, 2025, with the capital intended for further research and development activities and ongoing working capital.
- The shares were purchased by US investors through the company's US At-The-Market (ATM) facility.
Dec 4, 2025, 11:41 AM
Immuron Announces U.S. Department of Defense Award and Clinical Trial Update
IMRN
New Projects/Investments
Guidance Update
- Immuron Limited announced a new U.S. Department of Defense sub award with the Naval Medical Research Command and the Walter Reed Army Institute of Research.
- This award is for the development of two new oral therapeutics targeting Campylobacter and Shigella, utilizing Immuron's proprietary technology to produce hyper-immune bovine colostrum products for pre-clinical evaluation.
- Topline results from the Uniformed Services University's P2TD clinical study, which evaluated IMM-124E (the active ingredient in Travelan®) for maintaining gut health, are anticipated to be announced at the end of next week.
Dec 3, 2025, 11:35 AM
Immuron Receives FDA Approval for IMM-529 IND Application
IMRN
Product Launch
New Projects/Investments
- The U.S. Food and Drug Administration (FDA) has approved Immuron's Investigational New Drug (IND) application for IMM-529, allowing the clinical study to proceed.
- Immuron plans to initiate a Phase 2 clinical trial for IMM-529 in individuals with Clostridioides difficile infection (CDI) during the first half of 2026.
- Opportunity assessment projects a base case yearly revenue of US$400M for IMM-529, with approximately 98,000 patients potentially eligible if positioned at first recurrence.
Nov 5, 2025, 11:00 AM
Immuron Provides Clinical Trial Update on IMM-529 and Travelan
IMRN
New Projects/Investments
Guidance Update
- Immuron submitted an Investigational New Drug (IND) application for IMM-529 to the FDA on October 8, 2025, which is currently under active review. The company responded to an FDA request for additional clinical information and made minor updates to the clinical protocol on October 25, 2025.
- Topline data for the Uniformed Services University's Travelan® P2TD study has been delayed to the end of November 2025 from its original expectation of end of October 2025, due to a U.S. government shutdown.
- The results from the Travelan® P2TD study will play a pivotal role in shaping Immuron’s dosing strategy for its upcoming End-of-Phase 2 meeting with the FDA.
Oct 31, 2025, 10:00 AM
Immuron Provides Clinical Trial Update, Including Travelan® Data Delay
IMRN
New Projects/Investments
Guidance Update
- Immuron Limited (IMRN) announced a delay in topline data for its Travelan® P2TD study (n=851) from the Uniformed Services University, with results now expected by the end of November 2025 due to a U.S. government shutdown.
- The company's IMM-529 Investigational New Drug (IND) application for Clostridioides difficile infection is under active FDA review, and Immuron has submitted minor updates to the clinical protocol in response to an FDA request for additional information.
- The Travelan® P2TD study results will be pivotal in shaping Immuron's dosing strategy for its upcoming End-of-Phase 2 meeting with the U.S. Food and Drug Administration.
Oct 31, 2025, 1:34 AM
Immuron Launches PROIBS for Irritable Bowel Syndrome in Australia
IMRN
Product Launch
New Projects/Investments
- Immuron Limited (ASX: IMC; NASDAQ: IMRN) officially launched PROIBS® for Irritable Bowel Syndrome (IBS) into the Australian market on October 24, 2025.
- PROIBS® is a certified medical device for treating IBS symptoms, and Immuron has already received pharmacy orders for the product.
- The launch strategy focuses on online and selected pharmacies, supported by digital marketing and social media, timed for the peak festive season when IBS symptom triggers are highest.
- The Australian "Digestives & Intestinal Remedies" market, which includes IBS treatments, is estimated to generate AU$221.14 million in 2025 with a projected annual growth rate of 3.28%.
Oct 24, 2025, 12:01 AM
Quarterly earnings call transcripts for Immuron.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more